By the end of the second quarter, we had fully repaid the Sanofi Development Balance, which represented the outstanding amount due to Sanofi for their funding of prior collaboration development activities.
In context
said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron. "By the end of the second quarter, we had fully repaid the Sanofi Development Balance, which represented the outstanding amount due to Sanofi for their funding of prior collaboration development activities.
Verbatim from the company's earnings release at sec.gov, accessed 2026-09-26.
Said July 30, 2026 in the Regeneron Reports Second Quarter 2026 Financial and Operating Results. Regeneron Pharmaceuticals's CFO record: Regeneron Pharmaceuticals on the record. We publish quotes as the company released them and add no view on the company's results or shares.